ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in Chronic Obstructive Pulmonary Disease
American Journal of Respiratory Cell and Molecular Biology · 2025
DOI: 10.1165/rcmb.2024-0469oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2025. Verfasst von Justin Sui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Cell Movement, Macrophages, Alveolar, Pulmonary Emphysema. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Burroughs Wellcome Fund, Parker B. Francis Foundation.
Themen: COPD
Abstract (Originalsprache)
Macrophage-mediated inflammation drives various lung diseases, including chronic obstructive pulmonary disease (COPD). COPD macrophages have dysfunctional mitochondrial metabolism and function, which lead to a chronic inflammatory lung environment. However, the factors regulating this altered metabolism have not been elucidated. ANT1 (adenine nucleotide translocase 1) is a mitochondrial ATP transporter critical to mitochondrial metabolism. We demonstrate that human alveolar macrophages from patients with moderate COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 2) have reduced ANT1 expression, whereas macrophages from very severe COPD (GOLD stage 4) have elevated ANT1 compared with normal control subjects. Ant1-deficient mice were protected against cigarette smoke (CS)-induced emphysema, with failure of recruited immune cells to migrate into alveoli. Ant1-null alveolar macrophages had reduced ATP production and mitochondrial respiration, upregulated fewer inflammatory pathways after CS, and reduced migratory capacity. Conditional Ant1 knockout in Cx3cr1-positive monocytes and adoptive transfer of Ant1-deficient bone marrow into CS-treated mice phenocopied the migratory defect in the lung. Our data indicate that ANT1 is a critical regulator of lung macrophage inflammatory signaling and CS-triggered cell migration in the lung, suggesting that metabolic modulation may be a promising therapeutic avenue for COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Critical Care Medicine.
- Department of Cellular and Molecular Pathology, and.
- Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany; and.
- Institute of Experimental Pneumology, University Hospital, Ludwig-Maximilians University, Munich, Germany.
ORCID-Profile: Corrine R Kliment
Förderung
- NHLBI NIH HHS
- Burroughs Wellcome Fund
- Parker B. Francis Foundation
- National Heart, Lung, and Blood Institute
Zitieren
APA
Sui, J., Johnson, A. R., Kapellos, T. S., Shiva, S., & Kliment, C. R. (2025). ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2024-0469oc
Vancouver
Sui J, Johnson AR, Kapellos TS, Shiva S, Kliment CR. ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology. 2025. doi:10.1165/rcmb.2024-0469oc
BibTeX
@article{Sui2025,
author = {Sui, Justin and Johnson, Aaron R and Kapellos, Theodore S and Shiva, Sruti and Kliment, Corrine R},
title = {ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in Chronic Obstructive Pulmonary Disease},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
doi = {10.1165/rcmb.2024-0469oc}
}
EUVIMED